226 related articles for article (PubMed ID: 31215771)
1. Comprehensive epigenetic analyses reveal master regulators driving lung metastasis of breast cancer.
Li K; Xu C; Du Y; Junaid M; Kaushik AC; Wei DQ
J Cell Mol Med; 2019 Aug; 23(8):5415-5431. PubMed ID: 31215771
[TBL] [Abstract][Full Text] [Related]
2. The hyper-activation of transcriptional enhancers in breast cancer.
Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M
Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030
[TBL] [Abstract][Full Text] [Related]
3. Reversible Regulation of Promoter and Enhancer Histone Landscape by DNA Methylation in Mouse Embryonic Stem Cells.
King AD; Huang K; Rubbi L; Liu S; Wang CY; Wang Y; Pellegrini M; Fan G
Cell Rep; 2016 Sep; 17(1):289-302. PubMed ID: 27681438
[TBL] [Abstract][Full Text] [Related]
4. A novel HER2 gene body enhancer contributes to HER2 expression.
Liu Q; Kulak MV; Borcherding N; Maina PK; Zhang W; Weigel RJ; Qi HH
Oncogene; 2018 Feb; 37(5):687-694. PubMed ID: 29035388
[TBL] [Abstract][Full Text] [Related]
5. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis.
Han HJ; Russo J; Kohwi Y; Kohwi-Shigematsu T
Nature; 2008 Mar; 452(7184):187-93. PubMed ID: 18337816
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.
Alaterre E; Ovejero S; Herviou L; de Boussac H; Papadopoulos G; Kulis M; Boireau S; Robert N; Requirand G; Bruyer A; Cartron G; Vincent L; Martinez AM; Martin-Subero JI; Cavalli G; Moreaux J
Theranostics; 2022; 12(4):1715-1729. PubMed ID: 35198065
[No Abstract] [Full Text] [Related]
7. Overexpression of OCT4 induced by modulation of histone marks plays crucial role in breast cancer progression.
Kar S; Patra SK
Gene; 2018 Feb; 643():35-45. PubMed ID: 29203199
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation regulates discrimination of enhancers from promoters through a H3K4me1-H3K4me3 seesaw mechanism.
Sharifi-Zarchi A; Gerovska D; Adachi K; Totonchi M; Pezeshk H; Taft RJ; Schöler HR; Chitsaz H; Sadeghi M; Baharvand H; Araúzo-Bravo MJ
BMC Genomics; 2017 Dec; 18(1):964. PubMed ID: 29233090
[TBL] [Abstract][Full Text] [Related]
9. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.
Papageorgis P; Ozturk S; Lambert AW; Neophytou CM; Tzatsos A; Wong CK; Thiagalingam S; Constantinou AI
Breast Cancer Res; 2015 Jul; 17(1):98. PubMed ID: 26208975
[TBL] [Abstract][Full Text] [Related]
10. Identification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data Analysis.
Kikutake C; Yahara K
PLoS One; 2016; 11(4):e0152918. PubMed ID: 27042856
[TBL] [Abstract][Full Text] [Related]
11. Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain.
Cai WL; Greer CB; Chen JF; Arnal-Estapé A; Cao J; Yan Q; Nguyen DX
BMC Med Genomics; 2020 Mar; 13(1):33. PubMed ID: 32143622
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modifications, chromatin distribution and TP53 transcription in a model of breast cancer progression.
Santos GC; da Silva AP; Feldman L; Ventura GM; Vassetzky Y; de Moura Gallo CV
J Cell Biochem; 2015 Apr; 116(4):533-41. PubMed ID: 25358520
[TBL] [Abstract][Full Text] [Related]
13. The roles of epigenetics in cancer progression and metastasis.
Chen JF; Yan Q
Biochem J; 2021 Sep; 478(17):3373-3393. PubMed ID: 34520519
[TBL] [Abstract][Full Text] [Related]
14. Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchymal transition, and metastasis.
Azevedo H; Pessoa GC; de Luna Vitorino FN; Nsengimana J; Newton-Bishop J; Reis EM; da Cunha JPC; Jasiulionis MG
Clin Epigenetics; 2020 Aug; 12(1):127. PubMed ID: 32831131
[TBL] [Abstract][Full Text] [Related]
15. Large organized chromatin lysine domains help distinguish primitive from differentiated cell populations.
Madani Tonekaboni SA; Haibe-Kains B; Lupien M
Nat Commun; 2021 Jan; 12(1):499. PubMed ID: 33479238
[TBL] [Abstract][Full Text] [Related]
16. Broad H3K4me3 domains: Maintaining cellular identity and their implication in super-enhancer hijacking.
Kent D; Marchetti L; Mikulasova A; Russell LJ; Rico D
Bioessays; 2023 Oct; 45(10):e2200239. PubMed ID: 37350339
[TBL] [Abstract][Full Text] [Related]
17. EHMT2 is a metastasis regulator in breast cancer.
Kim K; Son MY; Jung CR; Kim DS; Cho HS
Biochem Biophys Res Commun; 2018 Feb; 496(2):758-762. PubMed ID: 29337058
[TBL] [Abstract][Full Text] [Related]
18. ITIH5 mediates epigenetic reprogramming of breast cancer cells.
Rose M; Kloten V; Noetzel E; Gola L; Ehling J; Heide T; Meurer SK; Gaiko-Shcherbak A; Sechi AS; Huth S; Weiskirchen R; Klaas O; Antonopoulos W; Lin Q; Wagner W; Veeck J; Gremse F; Steitz J; Knüchel R; Dahl E
Mol Cancer; 2017 Feb; 16(1):44. PubMed ID: 28231808
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide methylation analyses identifies Non-coding RNA genes dysregulated in breast tumours that metastasise to the brain.
Pangeni RP; Olivaries I; Huen D; Buzatto VC; Dawson TP; Ashton KM; Davis C; Brodbelt AR; Jenkinson MD; Bièche I; Yang L; Latif F; Darling JL; Warr TJ; Morris MR
Sci Rep; 2022 Jan; 12(1):1102. PubMed ID: 35058523
[TBL] [Abstract][Full Text] [Related]
20. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
